MTOR and gastric cancer: Since the PI3K/AKT/mTOR/HIF-1α axis drives tumour-promoting inflammation in H. pylori- and EBV-associated gastric cancer, agents that target this pathway may also inhibit the development of premalignant gastric lesions from completing malignancy [56].